Dare Bioscience earnings missed by $0.02, revenue fell short of estimates
Dare Bioscience (DARE) reported Q3 EPS of -$0.18, missing estimates by $0.02, and revenue of $47.63K, below the $1.82M consensus. The stock is down 27.81% in 3 months and 67.18% in 12 months. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
The combination of an EPS miss and a far-below-consensus revenue figure is typically bearish for liquidity-constrained biotech names, especially when the article provides no offsetting positive catalyst like guidance or trial progress.
Market read
Traders can use the reported miss versus consensus to reassess near-term risk and expectations for subsequent updates.
What to watch
The article does not include guidance, cash runway, or management commentary, which are often more important than the headline revenue miss for biotech micro-caps.
Background
The piece summarizes Dare Bioscience’s Q3 results versus analyst consensus and notes recent stock performance.
Ticker impact
Dare Bioscience reported Q3 EPS of -$0.18, missing by $0.02, and revenue of $47.63K versus $1.82M consensus.
Likely downward pressure as the market reprices the company’s ability to generate revenue and meet expectations.
The article provides the company’s own quarterly EPS and revenue versus consensus, which are direct drivers of post-earnings sentiment and positioning.
Market effects
Limited read-through to the broader biotech sector; this is a single micro-cap earnings miss with no stated sector-wide catalyst.
No clear regional spillover beyond small-cap biotech sentiment.
Minimal global relevance; the disclosure is company-specific.
Counterpoint
If the revenue miss reflects timing of milestone recognition rather than demand collapse, the stock could stabilize on any subsequent operational updates not covered here.
Key entities
- companyDare Bioscience
NASDAQ-listed biotech issuer reporting Q3 EPS and revenue versus consensus.
